ForCast Orthopedics

Effectively treating patients devastated by total joint infection via proprietary antibiotic delivery to reduce cost, morbidity and risk of amputation or death

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Longmont, CO, US
  • Currency USD
  • Founded June 2017
  • Employees 3
  • Incorporation Type C-corp
  • Website forcastortho.com

Company Summary

We improve treatment for infection of total replacement joints, a devastating condition that will affect 141k US patients ($740M), in 2024 living with a total knee or hip replacement. Using available antibiotics, our proprietary local delivery system achieves therapeutic concentrations to eradicate bacterial biofilm reducing patient morbidity, cost, and risk of failure. We have: feasibility, a regulatory pathway, issued IP, under a strong team.

Team

  • Jeff Castleberry
    CEO & President

    CEO, President/Co-Founder
    BSME, MBA, PE
    30+ years in med-tech, several established corporations and startup companies - emphasis in technical executive leadership
    Previous emerging company leadership:
    Vitalmetrics (Urotrack sold to Bard; and VitalVue sold to D+G - now Medtronic),
    Larren (acquired by Battelle)
    CardioOptics (tech & IP sold to Olympus)
    EndoShape (co-founded in 2008, ongoing)
    Allotrope Medical (ongoing)

  • Jared Foran, MD
    CSO

    Active Orthopedic Surgeon;
    CSO/Co-Founder and ADK Spacer inventor;
    Director of Total Joint Replacement OrthoColorado Hospital, St. Anthony Hospital;
    Editorial Board Journal of Arthroplasty;
    Section Editor AAOS OrthoInfo;
    17 years in medical research: Johns Hopkins, UCSD, Rush University, Panorama Orthopedics

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free